Resumen de acción SLS SELLAS Life Sciences Group, Inc. es una empresa biofarmacéutica clínica en fase avanzada que se centra en el desarrollo de nuevas inmunoterapias contra el cáncer para diversas indicaciones oncológicas en Estados Unidos. Saber más
Análisis de riesgos + 1 riesgos adicionales
Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de SELLAS Life Sciences Group, Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del SELLAS Life Sciences Group Precios históricos de las acciones Precio actual de la acción US$1.14 Máximo en las últimas 52 semanas US$1.72 Mínimo de 52 semanas US$0.50 Beta 2.41 Cambio en 1 mes 25.40% Variación en 3 meses 3.64% Cambio de 1 año 120.08% Variación en 3 años -77.56% Variación en 5 años -59.86% Variación desde la OPV -99.66%
Noticias y actualizaciones recientes
SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia Dec 11
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 inr/r AML Dec 10
SELLAS Life Sciences Group, Inc. Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers Nov 28
Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely Nov 23
New major risk - Financial position Nov 15
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia Oct 15 Ver más actualizaciones
SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia Dec 11
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 inr/r AML Dec 10
SELLAS Life Sciences Group, Inc. Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers Nov 28
Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely Nov 23
New major risk - Financial position Nov 15
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia Oct 15 SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million. Aug 02
SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million. Aug 01
SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia Jul 08
SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia Jun 25
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia Jun 18
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely Jun 18
Price target decreased by 17% to US$5.83 May 16
SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level May 03
SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024 May 01
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study Apr 30
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML Mar 26
New major risk - Shareholder dilution Mar 20 SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million. Mar 20
SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering. Mar 16
New major risk - Share price stability Mar 12
SELLAS Life Sciences Group, Inc. Announces Executive Changes Mar 08
SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Feb 17
SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients Jan 10 SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million. Jan 05
SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma Dec 28
Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia Dec 15
SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market Dec 09
Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia Dec 05
SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia Nov 29
Consensus EPS estimates fall by 19% Nov 16
SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-S Nov 14
New major risk - Negative shareholders equity Nov 11
SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global Meeting Nov 07
New major risk - Shareholder dilution Nov 03
SELLAS Life Sciences Group, Inc. Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia Oct 17
SELLAS Life Sciences Group, Inc. Provides Update on Phase 3 Regal Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia Oct 15
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas Oct 12
New minor risk - Share price stability Oct 12
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data in Lymphoma Cohort from Sls009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met Sep 22
Consensus EPS estimates upgraded to US$0.87 loss Aug 17
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely Jul 13
New major risk - Financial position Jul 02
SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma Jun 29
Sellas Life Sciences Group, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial of GFH009 in Acute Myeloid Leukemia Jun 23
Consensus EPS estimates fall by 12% Jun 01
Consensus EPS estimates fall by 18% May 18
Sellas Life Sciences Group, Inc. Announces Positive Topline Data from Gfh009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study May 05
Consensus revenue estimates increase by 200% Mar 23
Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021) Mar 18
Price target decreased by 25% to US$6.00 Mar 17
SELLAS Life Sciences Group, Inc. Appoints John T. Burns as Chief Financial Officer Feb 07
SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality Jan 06
SELLAS Life Sciences Group, Inc. Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies Dec 15
SELLAS Life Sciences Group, Inc. ’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned Dec 10
SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vivo Study Dec 02
Insufficient new directors Nov 16
SELLAS Life Sciences Group, Inc. Announces Update on Phase 3 Regal Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia Nov 15
SELLAS Life Sciences Group, Inc. Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (Pembrolizumab) in Patients with Wt1+ Platinum-Resistant Advanced Ovarian Cancer Nov 11
SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S Oct 12
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely Sep 20
Insufficient new directors Sep 09
SELLAS Life Sciences Group Announces Results from New Preclinical in Vitro Study for its Highly Selective CDK9 Inhibitor, GFH009 Aug 25
SELLAS Life Sciences Group, Inc. Announces Election of Katherine Bach Kalin to Its Board of Directors Aug 17
Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.30 loss in 2Q 2021) Aug 12
SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vitro Studies for CDK9 inhibitor, GFH009 Aug 11
SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study Aug 09
SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009 Jul 08
SELLAS Life Sciences Group, Inc. Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial Jun 28
SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo Jun 09
SELLAS Life Sciences Group, Inc. Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer May 27
Price target decreased to US$13.75 Apr 27
Insufficient new directors Apr 27
SELLAS Life Sciences Group, Inc. Launches Expand Access Program for Galinpepimut-S Apr 27
SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 08, 2022 Apr 26
SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study Apr 12
Price target decreased to US$13.75 Apr 07
Sellas Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China Apr 07
We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully Mar 08
Sellas Life Sciences Group, Inc. Announces Final Court Approval of Settlement of Securities Litigation Mar 01
Price target decreased to US$14.83 Feb 03
SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer Feb 02
SELLAS Life Sciences Group, Inc. Announces IND Acceptance for First Clinical Trial of GPS in China Jan 27
Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth? Nov 23
Consensus forecasts updated Aug 13
Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Are In A Position To Invest In Growth Jul 19
SELLAS Life Sciences Group, Inc. Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer Jul 01
SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo Jun 25
SELLAS Life Sciences updates on at-the-market offering Jun 02 Rentabilidad de los accionistas SLS US Biotechs Mercado US 7D 17.5% 2.0% 2.4% 1Y 120.1% -4.1% 25.0%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: SLS superó a la industria US Biotechs, que obtuvo un rendimiento del -4.1% el año pasado.
Rentabilidad vs. Mercado: SLS superó al mercado US, que obtuvo un rendimiento del 25% el año pasado.
Volatilidad de los precios Is SLS's price volatile compared to industry and market? SLS volatility SLS Average Weekly Movement 10.0% Biotechs Industry Average Movement 11.3% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.3%
Precio estable de las acciones: SLS no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de SLS (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa SELLAS Life Sciences Group, Inc. es una empresa biofarmacéutica clínica en fase avanzada que se dedica al desarrollo de inmunoterapias novedosas contra el cáncer para diversas indicaciones oncológicas en Estados Unidos. El principal producto candidato de la empresa es el galinpepimut-S (GPS), un agente inmunoterapéutico contra el cáncer dirigido contra el tumor de Wilms 1, que se encuentra en ensayos clínicos de fase 3 para el tratamiento de la leucemia mieloide aguda y en ensayos clínicos de fase 1/2 para el tratamiento del cáncer de ovario. Mantiene una colaboración estratégica con Merck & Co., Inc. para evaluar el GPS administrado en combinación con el bloqueador PD1 pembrolizumab en un ensayo clínico de fase 1/2 en el que participan pacientes de hasta cinco indicaciones oncológicas, incluidas neoplasias hematológicas y tumores sólidos; y con GenFleet Therapeutics (Shanghai), Inc. para el desarrollo y la comercialización de GFH009, un inhibidor de CDK9 de molécula pequeña altamente selectivo, actualmente en ensayos clínicos de fase 1. SELLAS Life Sciences Group, Inc. tiene su sede en Nueva York.
Mostrar más Resumen de fundamentos de SELLAS Life Sciences Group, Inc. ¿Cómo se comparan los beneficios e ingresos de SELLAS Life Sciences Group con su capitalización de mercado? Estadísticas fundamentales de SLS Capitalización bursátil US$80.94m Beneficios(TTM ) -US$32.28m Ingresos (TTM ) n/a
0.0x Ratio precio-ventas (PS)
-2.5x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de SLS Ingresos US$0 Coste de los ingresos US$0 Beneficio bruto US$0 Otros gastos US$32.28m Beneficios -US$32.28m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.46 Margen bruto 0.00% Margen de beneficio neto 0.00% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado SLS a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/22 06:14 Precio de las acciones al final del día 2025/01/22 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas SELLAS Life Sciences Group, Inc. está cubierta por 6 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución James Molloy Alliance Global Partners Li Wang Watsek Cantor Fitzgerald & Co. Joseph Pantginis H.C. Wainwright & Co.
Mostrar 3 más analistas 
